Last month, the DEA enthused the pharmaceutical industry but disappointed cannabis advocates by re-scheduling the drug Epidiolex—but not CBD, the cannabinoid that makes it work. Now word emerges of a letter to the DEA by the Food & Drug Administration essentially calling for the descheduling of CBD altogether.
Recent comments
10 weeks 1 day ago
15 weeks 6 days ago
26 weeks 6 days ago
27 weeks 6 days ago
29 weeks 3 days ago
29 weeks 6 days ago
30 weeks 1 day ago
34 weeks 4 days ago
35 weeks 5 days ago
35 weeks 5 days ago